Phillip A. Sharp, Director at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 11,250 shares at $275.00 ($3.1M) on 2025-01-23, disclosed to the SEC on 2025-01-24.
Scheduled sale ($3.1M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ALNY | SELL | 2022-02-11 | $4.5M | — | Filing → |
| ALNY | SELL | 2020-11-30 | $7.5M | — | Filing → |
| ALNY | SELL | 2020-02-13 | $3.9M | — | Filing → |